EA202092085A1 - ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ - Google Patents

ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA202092085A1
EA202092085A1 EA202092085A EA202092085A EA202092085A1 EA 202092085 A1 EA202092085 A1 EA 202092085A1 EA 202092085 A EA202092085 A EA 202092085A EA 202092085 A EA202092085 A EA 202092085A EA 202092085 A1 EA202092085 A1 EA 202092085A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gib
application
antibodies against
therapeutic antibodies
spla2
Prior art date
Application number
EA202092085A
Other languages
English (en)
Inventor
Бланш Тамарит
Жак Тез
Original Assignee
Диаккюрат
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Диаккюрат filed Critical Диаккюрат
Publication of EA202092085A1 publication Critical patent/EA202092085A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Настоящее изобретение касается человеческих или гуманизованных антител, связывающих PLA2-GIB, их получения и их применения. Эти антитела проявляют полезные характеристики, в частности, для терапевтических и диагностических целей.
EA202092085A 2018-03-02 2019-03-04 ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ EA202092085A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305229.9A EP3533460A1 (en) 2018-03-02 2018-03-02 Therapeutic anti-spla2-gib antibodies and the uses thereof
PCT/EP2019/055255 WO2019166665A1 (en) 2018-03-02 2019-03-04 Therapeutic anti-spla2-gib antibodies and the uses thereof

Publications (1)

Publication Number Publication Date
EA202092085A1 true EA202092085A1 (ru) 2021-02-09

Family

ID=61691417

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092085A EA202092085A1 (ru) 2018-03-02 2019-03-04 ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ

Country Status (15)

Country Link
US (1) US20210047432A1 (ru)
EP (2) EP3533460A1 (ru)
JP (1) JP2021515554A (ru)
KR (1) KR20200138726A (ru)
CN (1) CN112074292A (ru)
AR (1) AR114129A1 (ru)
AU (1) AU2019226674A1 (ru)
BR (1) BR112020017956A2 (ru)
CA (1) CA3091992A1 (ru)
EA (1) EA202092085A1 (ru)
IL (1) IL277007A (ru)
MX (1) MX2020009130A (ru)
SG (1) SG11202008044PA (ru)
TW (1) TW202000230A (ru)
WO (1) WO2019166665A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017037041A1 (en) 2015-08-31 2017-03-09 Diaccurate Use of indole compounds to stimulate the immune system
EP3693063A1 (en) * 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
EP3858357A1 (en) 2020-01-28 2021-08-04 Diaccurate Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib
WO2021214039A1 (en) 2020-04-21 2021-10-28 Diaccurate Spla2hgib-binding molecules and uses thereof
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
JP2009522234A (ja) * 2005-12-29 2009-06-11 イミュファルマ・フランス・エスアー ホスホリパーゼａ２を阻害する組成物および方法
EP2581388A1 (en) * 2011-10-14 2013-04-17 Centre National de la Recherche Scientifique (CNRS) Anti-sPLA2-V antibodies and uses thereof
US9657109B2 (en) * 2012-11-02 2017-05-23 Wisconsin Alumni Research Foundation Compositions and methods for the treatment of systemic inflammatory response syndromes
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression

Also Published As

Publication number Publication date
CA3091992A1 (en) 2019-09-06
CN112074292A (zh) 2020-12-11
AR114129A1 (es) 2020-07-22
SG11202008044PA (en) 2020-09-29
TW202000230A (zh) 2020-01-01
US20210047432A1 (en) 2021-02-18
AU2019226674A1 (en) 2020-09-17
IL277007A (en) 2020-10-29
KR20200138726A (ko) 2020-12-10
EP3758743A1 (en) 2021-01-06
EP3533460A1 (en) 2019-09-04
MX2020009130A (es) 2021-01-08
JP2021515554A (ja) 2021-06-24
BR112020017956A2 (pt) 2020-12-22
WO2019166665A1 (en) 2019-09-06

Similar Documents

Publication Publication Date Title
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
PH12019500545A1 (en) Cd3 binding antibodies
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201892294A1 (ru) Антитела и композиции против tim-3
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
MX2018016404A (es) Anticuerpos de union a cd3.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201791270A1 (ru) Модифицированные april-связывающие антитела
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
EA202092306A1 (ru) Анти-cd24 композиции и их применения
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201991005A1 (ru) Антитела и полипептиды, направленные против cd127
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202190235A1 (ru) Антитела к cd33 и способы их применения
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA201990978A1 (ru) Антитела против pd-1